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Abstract
The aim of this pilot study was to determine health-related quality of life (HRQoL) in patients with history of medication overuse
headache (MOH) after detoxiﬁcation and a headache-speciﬁc inpatient rehabilitation program and to receive necessary information
for future prospective studies.
HRQoLandheadache-relateddisabilitywere cross-sectionallymeasuredbyShort Form36 (SF-36),Hospital Anxiety andDepression
Scale (HADS),Migraine Disability Score (MIDAS), Coping StrategiesQuestionnaire (CSQ), andSymptomChecklist 90 revised (SCL-90-
R). SF-36, HADS, and SCL-90-R data were compared to German population norms, stratiﬁed by age, sex, and comorbidities.
Fifty-onepatients (72.5% females,meanage47.3 years)were includedwith anaverageheadachedurationof 25.3 years.Moderate to
high levels of headache were reported on the MIDAS VAS at 6.51 (range 0–10); SF-36 bodily pain was 40.3 (norm=59.0, P< .001,
100=best). Impaired functioning averaged at 78.4 (100=no impairment) on the MIDAS. In contrast, SF-36 physical functioning was
comparable to the norm (mean: 78.4, norm=81.8,P= .63). All other SF-36 scaleswere signiﬁcantly lower than expected from the norm
(all P< .001). The scales depression, anxiety, obsessive-compulsive, and interpersonal sensitivity were signiﬁcantly affected, whereas
the levels of SCL-90-R schizophrenia nuclear and schizotypia were not lower than the norm. Coping with pain was moderate.
This pilot study is the ﬁrst that presents a comprehensive and simultaneously speciﬁc assessment of health and quality of life of
MOH patients after detoxiﬁcation and inpatient rehabilitation. Moderate to high levels of pain and self-reported disability owing to
headache were observed, whereas physical function on the SF-36 was not different from the expected level of the norm. Mental
health was substantially affected in several dimensions, which had been described to reduce the ability to cope with pain. MOH
patients seem to have high expectations of functionality, low symptomatology, and intact well-being.
Abbreviations: CSQ = coping strategies questionnaire, ES = effect size, HADS = Hospital Anxiety and Depression Scale, m =
Mean, max =maximum, MCS =mental component summary, MIDAS =Migraine Disability Assessment Score, MOH =medication
overuse headache, NRS = numeric rating scale, NSAIDs = non-steroidal anti-inﬂammatory drugs, p = type I error of the Wilcoxon
test, PCS = physical component summary, PROM = patient-reported outcome measure, SCL-90-R = Symptom Checklist 90
revised, sd= standard deviation, SF-36= short form 36, VAS= visual analogue scale, ZKP= Zurzach headache program (Zurzacher
Kopfschmerz Programm).
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1atic headache medication on at least 10 days per month (for
triptans, opioids, ergotamin, combination of analgesics) or 15
(for simple analgesics, salicylate, non-steroidal anti-inﬂammatory
drugs [NSAIDs]) during a period of a minimum of 3 months.[1]
The deﬁnition of MOH is focused on the substance and duration
of substance use, but not on the primary form of headache (e.g.,
tension-type headache or migraine), which is the underlying
etiology for substance overuse. MOH is common among patients
with chronic headache and has a prevalence of up to 1% in the
adult population of different countries.[2,3] In the EU, the total
annual cost of MOH among adults aged 18 to 65 years amounts
to €37 billion reﬂecting the high public health impact.[4]
Compared to patients with migraine without medication
overuse, MOH was associated with more depression, lower self-
efﬁcacy, and weak pain-coping, but more pain-induced disability
when measured by self-assessment instruments.[5] MOH patients
suffered from anxiety and depression and reduced quality of life
as rated on the Short Form 36 (SF-36).[6,7]
The withdrawal of the overused acute headache medication is
considered as the causal treatment of MOH.[8,9] A majority of
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substances.[7] Average medication use after detoxiﬁcation
decreased by about 14% and average annual costs for medication
by 24%.[10] Inpatient and outpatient detoxiﬁcation programs are
effective in reducing medication and in decreasing headache
frequency.[11] Dropout rates in outpatient programs are higher
than in inpatient programs.[11] In particular, patients with
“complicated MOH” beneﬁt from a structured detoxiﬁcation
program.[12] Nevertheless, there is a lack of studies providing
evidence for speciﬁc treatment strategies.[13] However, consensus
reﬂected in guidelines highlights withdrawal as the major
strategy.[3,14]
After detoxiﬁcation, the relapse rate of MOH patients is high,
especially in the ﬁrst year, but decreases thereafter.[15] Experts
recommend interdisciplinary rehabilitation after the detoxiﬁca-
tion to ensure long-lasting effects.[16] Further goals of multidisci-
plinary treatment are education, improvement of therapy to
reduce headache frequency, and to increase quality of life.[16]
There is lacking evidence as to which therapeutic elements have to
be part of a multidisciplinary treatment approach.
There is only little empirical research about intensive
multidisciplinary headache treatment programs for MOH,
migraine, and tension-type headache, but some multimodal
treatment approaches were shown to be effective for MOH and
primary headaches.[17,18] The study of Gunreben et al[18]
presented pre- and postdata of intensive multidisciplinary pain
program in terms of number of headache days per month,
headache intensity, and depression. Pre- and post-data of
standardized outcome instruments were not presented. At
present, there are no published data on comprehensive health-
related quality of life (HRQoL) from patients who underwent an
intensive interdisciplinary MOH rehabilitation program after
detoxiﬁcation available.
The goal of this study was to quantify comprehensively as well
as condition-speciﬁcally HRQoL for patients with MOH after
detoxiﬁcation and subsequent MOH rehabilitation program
using standardized patient-reported outcome measures
(PROMs). Data were compared to available normative values
obtained by general population surveys. The hypothesis was that
there were still health deﬁcits in some health dimensions,
especially in mental and psychosocial health scales, even after
successful detoxiﬁcation and subsequent rehabilitation. The
ﬁndings help to get an idea of the health and impairment of those
patients as well as the usefulness and feasibility of the generic and
condition-speciﬁc PROMs. This should give a basis to plan future
prospective studies, which quantify intervention effects.2. Methods
2.1. Patients
This cross-sectional pilot study examined patients having
participated in the Zurzach headache program (Zurzacher
Kopfschmerz Programm, ZKP) at the rehabilitation center
“RehaClinic,” Bad Zurzach, Switzerland, between July 2012
and June 2014, by means of a postal survey. The conditions for
entry to the ZKP were diagnosis of MOH, conﬁrmed by board-
certiﬁed neurologists. Cross-sectional assessment was performed
0.5 to 2.5 years after the end of the ZKP.
Exclusion criteria for the ZKP and the study were: Abuse of
benzodiazepines; serious psychiatric comorbidity such as psy-
chosis or suicidality; severe somatic illness requiring speciﬁc
treatment and preventing participation in the ZKP, for example,2cancer, inﬂammatory rheumatic disease, serious other neurologi-
cal diseases that prevented participation in the program (e.g.,
dementia); nonadherence for the correct intake of prescribed
medication or regular participation in all therapies of the ZKP;
insufﬁcient German language skills to understand the study
questionnaire. The study protocol was approved by the
independent local ethics commission (Health Department in
Aarau, Switzerland, EK AG 2008/026). Written, signed informed
consent was obtained from all participants.2.2. Intervention
Withdrawal of overused medication was performed in an acute
hospital or, for a few exceptions, on an outpatient basis and with
neurological supervision, directly before admission. This means
that detoxiﬁcation was completed before inpatient rehabilitation.
During detoxiﬁcation, all analgesics and triptans were stopped on
the ﬁrst day and were replaced by prednisone 100mg per day for
5 days.[19,20] Prophylactic medication was started on the ﬁrst day
according to the treatment recommendations of the Swiss
Headache Society.[21] If an analgesic reserve was needed, a
substance from a class of acute headache medication other than
the previously (over)used was provided, for example, an NSAID
instead of a triptan.
Immediately after acute withdrawal, patients were admitted to
theZKP, a comprehensive andmultimodal inpatient rehabilitation
lasting 2 to 3 weeks which was established in 2010. The concept
includes multidisciplinary therapies provided by a team of
neurologists, behavioural and clinical psychologists, physical
therapists, and nurses. The concept is standardized and in line
with international recommendations.[16] Eachweek, patients had3
physician visits and 2 to 3 consultations with psychologists,
including patient education. The standardized weekly program
also included daily physical therapy and aerobic exercise, 2
sessions of relaxation therapy, 2 to3 sessions ofmedicalmassage, 2
to 3 sessions of acupuncture if applicable, individual use of thermal
water, and medical training therapy. The treatment team met
weekly to discuss the progress of the patients. During the period of
this study, the physicians and therapists remained stable.2.3. Measures
All medical records from neurologists and other physicians were
obtained to conﬁrm diagnosis ofMOH, determine comorbidities,
body height, and weight. Sociodemographic and disease-relevant
data were measured using a standardized questionnaire that has
already shown its usefulness in other studies.[22,23] The pain
Numeric Rating Scale (NRS) was used, as it had been described to
be easier to comprehend and to handle than the visual analogue
scale (VAS), with comparable psychometric properties.[24,25]
The Short Form 36 (SF-36) is a self-assessment questionnaire
that is used to measure health and HRQoL on 4 physical/somatic
scales (physical functioning, role physical, bodily pain, general
health) and 4 psychosocial/mental scales (vitality, social
functioning, role emotional, mental health) comprising 36
items.[26,27] A complex linear-combination of all 8 scales provides
the summary scales, with speciﬁc weights for the physical
component summary (PCS) and different ones for the mental
component summary (MCS).[27] Population survey-based nor-
mative data for the SF-36 exist and allow quantiﬁcation stratiﬁed
by sex, age (5-year classes), and comorbidity (present/absent).[28]
These data had been collected in Germany, having comparable
language and cultural properties, as in the German-speaking part
[28,29] [29,34]
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used generic outcome measure having proven its validity and
reliability in numerous studies.[30] Validity in measurement of
pain, physical and social function, depression, and anxiety in
chronic pain conditions have been proven.[24]
The Migraine Disability Assessment Score (MIDAS) was used
to assess the condition-speciﬁc disability.[31,32] It records
headache-related disability by measuring missing days because
of headache in the last 3 months on 5 items: school or paid work:
number of days missed, number of days with half performance or
lower; household work: number of days missed, number of days
with half performance or lower; family, social or leisure activities:
number of days missed.[31] The number of days is summed up
using items 1 to 5 and rescaled to a score of 0=all days missed/
disabled and 100= full-working capacity on all days. In addition,
the number of days with headache in the last 3 months is
recorded, and pain is quantiﬁed on an NRS 0 to 10.
The Coping Strategies Questionnaire (CSQ) evaluates active
and passive coping strategies and is internationally used in
chronic pain conditions.[33–35] The German version is cross-
culturally adapted and validated.[34] Catastrophizing and the 2
items “control over pain” and “ability to decrease pain” were
included in this study because their clinical signiﬁcance for MOH
was considered to be most appropriate and the responsiveness to
change was optimal.[24,36]
Psychopathological assessment was performed by the Hospital
Anxiety and Depression Scale (HADS) and the Symptom
Checklist 90 revised (SCL-90-R). This was done because the
association between psychopathological symptoms and headache
had been shown to be elevated in migraine patients when
compared to controls without migraine, whereas this was not the
case in patients with tension-type headache.[37]
The HADS is a questionnaire for patients of nonpsychiatric
settings consisting of 14 items, 7 for anxiety and 7 for
depression.[38,39] German population survey-based normative
data are stratiﬁed by sex and age (10-year classes).[40]
The SCL-90-R is a self-report of psychopathological symp-
toms, especially for nonpsychiatric populations.[41,42] Patients
rate distress on a 5-step Likert-scale on 90 items. Based on our
clinical experience, the following speciﬁc scales that are assumed
to be most important for MOH were selected: obsessive-
compulsive, interpersonal sensitivity, schizotypia, and schizo-
phrenic nuclear. The latter 2 scales are constructs based on a large
population-based survey.[43] Depression and anxiety were
already covered by the HADS. Population norms, stratiﬁed by
sex and age using 10-year intervals from Germany, were used for
comparison.[42] The normative data from the scale paranoid
ideation were compared with the scale schizophrenia nuclear and
those of the scale psychoticism were compared with the scale
schizotypia.[44,45]2.4. Statistical analysis
Unless indicated differently (e.g., for the pain NRS), all
instrument scores were scaled from 0=worst to 100=best
health/function/ability in accordance with the original scoring of
the SF-36 to ease comparison with scores obtained from other
instruments.[23] The speciﬁc “missing rules” of the instruments
had to be fulﬁlled for determination of the scales. This means that
at least 50% of the items had to be completed for each of the SF-
36 scales and 6 of 7 for each of the HADS scales.[27,38] For the
CSQ, MIDAS, and the SCL-90-R, no “missing rules” were
speciﬁed in the original reports; thus, the “2 of 3 (67%) rule”was3applied as described for other instruments. Owing to the
metric properties of the determination of the scales and to have a
useful minimal number for metric statistics, a minimal number of
n>30 was set to be required with a wishful number of n ≥50 for
this pilot study.[46]
All analyses were performed using the statistical software
package IBM SPSS 22.0 for Windows (SPSS Inc, Chicago, IL).
Two-tailed signiﬁcance tests were performed by the nonpara-
metric Wilcoxon test for continuous data to ensure appropriate-
ness for all distributions, not only the Gaussian.3. Results
3.1. Patients
Between July 2012 and June 2014, 106 patients with a conﬁrmed
MOH diagnosis were treated in the program, of which 83 (78%)
could be contacted by telephone (max. 7 attempts). The
remaining 23 received the assessment set without previous
contact. Of those who were contacted by phone, 8 refused
participation, and 7 had insufﬁcient German language skills. Of
the 91 mailed sets, 51 (56%) were returned with complete data.
Of the 40 sets that were not returned, 4 patients withdrew
willingness to participate; for 36 sets, no reasons for decline were
given (Fig. 1). Time since the end of the pain program ranged
between 0.5 and 2.5 years (Table 1).
The median study participant was female, middle-aged, lived
with a partner or spouse, was educated to the level of vocational
training or less, worked full-time, did not smoke, and performed
sports up to 2hours/week (Table 1). The individuals had suffered
from headache for 25 years, had taken 1 substance against
headache in the last 2 weeks before assessment, and felt much
better or slightly better in comparison to their state before the
pain program.
In the last 14 days before assessment, 2 or 3 different pain
medications (either acute or prophylactic) were taken by 45%
of patients. A minority still took acute headache medication:
24% paracetamol/NSAIDs, 14% triptans, and 2% opioids.
Prophylactic medication (e.g., riboﬂavin or topiramate) was
taken by 45%.3.2. Outcome
Pain intensity levels of the pain scales were moderate at the time
of the assessment (mean: 3.3/10 points=maximal pain) up to
severe (6.8/10) at the worst moment of the last 7 days before,
corresponding to a score of 6.5 of 10 on the MIDAS (Table 2).
The MIDAS revealed on average 40.1% (37.7/92) days with
headache within the last 3 months. Of the 51 patients, 33 (65%)
reported <45 days with headache in the last 3 months. The
number of days with impaired function owing to headache (sum
of the items 1–5) averaged to a value of 59.5 (of 276), which
corresponds to 21.6%. Mean pain on the SF-36 (last 4 weeks)
was 40.3 (100=no pain, which would correspond to 6.0 on the
VAS) and is signiﬁcantly higher than expected from the
normative data for the general population (mean: 58.1, P< .001).
Physical functioning was not affected on the SF-36 when
compared to the norm (means: 78.4 vs. 81.8, P= .66; 100=best).
All other scales of the SF-36 showed highly signiﬁcant (P .001)
impairments with levels far from the expected scores, for
example, general health 48.7 versus 62.1 and social functioning
56.8 versus 82.1. The only exception is SF-36 mental health: 59.7
versus 68.5=norm, P= .04.
Table 1
Sociodemographic and disease-relevant data (n=51).
%
Sex Female 73
Education Basic school (8–9 years) 18
Vocational training 39
college/high school/university 43
Living With partner/spouse 76
Smoking Yes 29
Sports >2 h/wk 37
>0–2 h/wk 47
None 16
Working capacity Full (42 h/wk) 55
Part 9
None 16
Retired 10
Primary type of headache Migaine 90
(before MOH therapy) Tension-type headache 8
Persistent headache attributed to craniotomy 2
Medication: number None 22
(last 14 days) 1 Substance 33
2 Substances 29
3 Substances 16
Medication: therapeutic Paracetamol/NSAIDs 24
substances (last 14 days) Opioids 2
Triptans 14
Medication: prophylactic Riboﬂavin 29
substances (last 14 days) Topiramate 16
Medication Others
∗
55
Transition Much better 37
(compared to the state Slightly better 31
before the pain program) Almost the same 24
Slightly worse 8
Much worse 0
Mean (sd)
Age, y 47.3 (11.8)
Body mass index, kg/m2 25.3 (14.4)
Duration headache, y 24.8 (4.8)
Time since pain program, y 1.3 (0.6)
MOH=medication overuse headache, NSAIDs=nonsteroidal anti-inﬂammatory drugs, sd= standard
deviation.
∗
Not related to headache.
ZKP patients with confirmed 
MOH diagnosis
n=106
Contacted by phone
n=83
No contact by phone
n=23
• Refused participation n=8
• Insufficient language skills n=7
Postal mail of questionnaire
n=91
• Withdrawal of willingness to participate n=4
• Withdrawal for unknown reason n=36
Complete data 
included in analysis
n=51
Figure 1. Patient selection. MOH=medication overuse headache, ZKP=Zurzach headache program (Zurzacher Kopfschmerz Programm).
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4Consistently, HADS depression and anxiety were much higher
than expected from the normative levels: 67.6 versus 78.1, P= .02
and 63.3 versus 76.5, P< .001. The same was true for the
obsessive/compulsive scale (74.1 vs. 87.4) and, somewhat less,
for the interpersonal sensitivity scale (79.9 vs. 89.6) of the SCL-
90-R. In contrast, patients were not more schizotypal (84.4 vs.
88.8, P= .81), but were less “schizophrenic” (schizophrenia
nuclear: 94.4 vs. 95.1) than expected. In the SCL-90-R
schizophrenia nuclear, the median of the patients was 100,
whereas the mean norm was 95.3, which led to a signiﬁcant
difference (P= .03) in favor of the patients.
Coping with pain showed moderate levels in the middle range
of the scale on the CSQ (catastrophizing: 53.1). This corresponds
to the 37% replies of “much better” and 31% “slightly better” on
the transition item (Table 1).4. Discussion
This cross-sectional pilot study quantiﬁed health and HRQoL in
patients with history of MOH after detoxiﬁcation and a
subsequent headache-speciﬁc inpatient rehabilitation program
with a comprehensive set of generic and condition-speciﬁc
questionnaires. The study did not aim to quantify treatment
effects, but to provide data about patients’ state of health and
appropriateness of the assessment as base for planning future
prospective studies. Where possible, empirical data were
compared to normative values obtained by general population
surveys. The hypothesis that deﬁcits persisted in some health
dimensions after withdrawal and subsequent rehabilitation was
conﬁrmed and psychopathological symptoms persisted. In our
sample,MOHwas associated with female sex, middle age (40–50
years), and relatively low education level. These characteristics
are consistent with many other European studies.[6,18,47–51]
Substantial burden of headache was measured by the NRS, the
MIDAS, and the SF-36—the score of SF-36 bodily pain showed
Table 2
Outcomes for medication overuse headache patients after an inpatient pain program (n = 51).
Form Scale
Patient Norm
m sd m sd P
Pain VAS At the moment (10 = max) 3.3 2.8 — — —
At its worst of 7 days (10 = max) 6.8 2.5 — — —
At its best of 7 days (10 = max) 1.9 1.9 — — —
MIDAS Sum of items 1–5 (276 = max) 59.5 64.8 — — —
Days with headache (92 = max) 37.7 29.9 — — —
Intensity of headache (10 = max) 6.5 2.0 — — —
Total score (100 = best) 78.4 23.5 — — —
SF-36 Physical functioning 78.4 21.4 81.8 8.7 .63
Role physical 50.5 23.8 75.7 9.8 <.001
Bodily pain 40.3 20.3 58.1 9.2 <.001
General health 48.7 21.5 62.1 6.8 <.001
Vitality 41.3 21.8 55.5 3.6 <.001
Social functioning 56.8 28.1 82.1 3.6 <.001
Role emotional 64.2 29.5 84.2 5.1 <.001
Mental health 59.7 22.3 68.5 3.3 .04
Physical component summary 41.7 6.7 45.9 4.0 .001
Mental component summary 39.4 13.9 49.1 1.3 <.001
HADS Depression 67.6 24.1 78.1 4.0 .02
Anxiety 63.3 19.4 76.5 1.9 <.001
SCL-90-R Schizophrenia nuclear 94.4 12.2 95.1 1.7 .03
Schizotypia 84.4 18.4 88.8 1.8 .81
Interpersonal sensitivity 79.9 16.8 89.6 2.1 <.001
Obsessive compulsive 74.1 19.1 87.4 2.1 <.001
CSQ Catastrophizing 53.1 23.5 — — —
Control pain 49.7 23.2 — — —
Decrease pain 49.7 23.5 — — —
CSQ=Coping strategies questionnaire, HADS=Hospital Anxiety and Depression Scale, m=mean, max=maximum, MIDAS=Migraine Disability Questionnaire, p= type I error of the Wilcoxon test: patient
versus norm data, SCL-90-R=Symptom checklist 90 revised, sd= standard deviation, SF-36=Short form 36, VAS= visual analogue scale. Scaling (where not indicated differently): 0=worst, maximal
symptoms to 100=best, no symptoms.
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true for all other scales of the SF-36, except for the SF-36 physical
functioning. The number of days with headache and with
consequent limitations at work and in daily life on the MIDAS
showed levels compatible with signiﬁcant burden. Comparison to
norms is not possible because of lack of data. Affective symptoms
as well as obsessive and compulsive symptoms and interpersonal
sensitivity were signiﬁcantly increased, whereas schizotypal or
schizophrenic symptoms were not. Finally, ability to cope with
pain was moderate and comparable to other chronic pain
patients.[26]
The pattern of our empirical SF-36 scores compared with that
of the norm scores was similar to that of previous studies: the
highest differences were in role physical, bodily pain, social
functioning, and the lowest were in physical functioning. This
pattern was consistent with a population-based sample in Spain
(n=74 MOH).[6] However, in that study, the smallest difference
in SF-36 physical functioning still reached signiﬁcance, whereas it
did not in our data. A previously conducted survey by the same
study group (n=22MOH) found SF-36 scores, which were much
lower than those of our patients for physical functioning (59.2 vs.
78.4 in our study) and mental health (48.2 vs. 59.7 in our study),
whereas the other scales were comparable.[52]
To the best of our knowledge, no further study exists, using
either the SF-36 or the SF-12 to compare MOH (after
detoxiﬁcation and headache speciﬁc rehabilitation) with healthy
controls, whereas several studies of chronic daily headache
sufferers have been published. One review of comparative studies
concluded that 3 of 5 studies having used SF-36 or SF-125suggested that MOH patients have worse HRQoL than those
with chronic headache without medication overuse.[53] However,
the reviewed data presented mean differences between different
studies in bar plots and did not provide the exact ﬁgures.[53] For
this reason, it is important to know—besides the previous
diagnosis apart from MOH—whether the patients had a history
of MOH or not. The primary diagnosis of most patients in this
study was migraine (92%, Table 1).
The SF-36 PCS and MCS scores of this present study were
comparable to a study conducted at the 6-month follow-up after
an inpatient withdrawal therapy for MOH: the mean PCS at
follow-up was 43.2 versus 41.7 in our study, the MCS 42.2
versus 39.4, respectively.[54] At the 6-month follow-up, both
scores showed signiﬁcant improvement when compared to
baseline.[54]
In a study about the effectiveness of an intensive multidisci-
plinary headache treatment program lasting 96hours, pretreat-
ment PCS was 37.9 and MCS was 39.0.[18] Post-treatment SF-36
were not reported. However, patients signiﬁcantly improved in
the depression and in the number of days with headache, but not
on pain intensity.
On the MIDAS, MOH-related disability continuously de-
creased during the follow-up period after an inpatient withdraw-
al treatment from an average of 70.8 (MIDAS sum of items 1–5)
before treatment to 34.1 one year later and to 17.0 at 5 years.[55]
These post-treatment levels were lower than ours at 59.5. In
contrast, our data are comparable to the baselineMIDAS score of
59.9 of a multicenter, multinational study.[56] Those cases
improved to a score of 25.7 at the 6-month follow-up. This means
Benz et al. Medicine (2017) 96:47 Medicinethat the posttreatment scores of our patients indicated much
greater disability because of headache than in the 2 aforemen-
tioned studies. Based on the observed improvements on the
MIDAS score as reported in 4 treatment studies, it may be
hypothesized that our sample was a selection of highly disabled
patients admitted to intensive inpatient rehabilitation.[55–58]
Scores for schizophrenia, and equally schizotypia, were
signiﬁcantly lower, but scores for interpersonal sensitivity and
obsessive compulsive (symptoms) were signiﬁcantly higher, and
scores for depression and anxiety were higher than expected from
the norm. Schizophrenia nuclear is a milder version of the core
diagnostic symptoms of psychosis, which is thought to be a
biologically based perception disorder.[43] Schizotypal signs are
characterized by generalized distrust, odd interpersonal beliefs,
and paranoid ideation, which lead to a distorted perception of the
environment, inﬂuenced by psychosocial conditions.[43] The 2
symptom dimensions show relatively high overlap on the
psychopathological level, but coincide only partly.[43] They are
expression of psychotic symptoms with different levels of severity
and persistence on the continuum of the psychotic phenotype.[59]
This is consistent with previous studies.MOHwas associatedwith
obsessive-compulsive disorders; in one study, the prevalence of the
latter was 28%.[60] Psychiatric comorbidities are predictors for
prognosis and response to treatment.[60–62]A small study showeda
signiﬁcantly increased risk of suffering from overall mood
disorders (odds ratio, OR=4.5), anxiety (OR=5.0) and disorders
associated with the use of psychoactive substances other than
analgesics (OR=7.6) in MOH sufferers when compared to
patients withmigraine only (n=41 in both groups).[63] TheHADS
anxiety score of 63.3 in our study is comparable to a 3-month
follow-up score of 66.7[62] and a 6-month follow-up score of
66.2,[56] whereas the depression score in our study (67.6) is lower
when compared to the aforementioned studies (81.0 at 3-month
follow-up; 80.4 at 6-month follow-up).
In this cross-sectional pilot study, the combination of generic
and condition-speciﬁc assessments provided comprehensive but
also disease-speciﬁc measurements of health and HRQoL. This is
the strength of the study. The questionnaire set gave moderate
respondent and administrative burden and the single instruments
turned out to be appropriate for MOH. Furthermore, the
instruments were internationally used, validated, and standard-
ized, and allowed comparison of empirical with normative data
for some instruments. Even after completion of the therapies,
deﬁcits on various health dimensions could still be measured as
compared to normative data. This means that the instruments
used did not reveal ceiling effects, which may have reduced
validity of the measurements. Further strengths were a compact
cohort with representative sociodemographic characteristics and
a standardized intervention throughout the whole period of
treatment.
The cross-sectional design of this study does not allow the
evaluation of health changes or evaluation of the therapeutic
effects of the rehabilitation program. Furthermore, this study
does not allow a conclusion about the compliance of the patients
to the recommended treatment and instructions after the
rehabilitation program. However, the study aimed to provide
basic data on the state of health and quality of life after speciﬁc
treatment for MOH in a sample of severely affected patients. A
further limitation is that the time interval between the completion
of the headache program and the postal survey varied between
0.5 and 2.5 years. The sample size of 51 out of a patient
population of 106 with conﬁrmed MOH diagnosis is limited and
cannot exclude a selection bias, for example, towards patients6with better health status, which is an inherent problem in every
voluntary survey.
This study is the ﬁrst that presents a comprehensive and
simultaneously speciﬁc assessment of health and quality of life of
MOH patients after detoxiﬁcation and inpatient rehabilitation.
Moderate to high levels of pain and self-reported disability
towing to headache were observed, whereas physical function on
the SF-36 was not different from the expected level of the norm.
This may be because of high expectations of functionality and
corresponds to low self-reported coping with pain, relatively high
catastrophizing, depression, and anxiety. The data of this cross-
sectional pilot study sampled over 2 years can be taken as valid
estimate of the outcome of the pain program in our clinic.
Generalizability to other pain programs should be done with care
because comparable data with standardized instruments are
lacking from other programs. Future longitudinal data will
provide quantiﬁcation of treatment effects and reﬁne insight into
processes of treatment, individual developments, and need
speciﬁc to MOH during the course of treatment and recovery.Acknowledgments
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